ArticleACS omega2025
Preparation, Characterization, and Pharmacokinetic Evaluation of BerbiQ: An Advanced Bioavailable Berberine Formulation Using OMICS Technology by Synergistic Complexation.
Article in ACS omega, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Enhanced antimicrobial activity, mechanical and dielectric properties of styrene butadiene rubber vulcanizates designed for protection products.Scientific reports · 2026Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
A novel bioavailable berberine formulation, BerbiQ, was developed using OMICS technology by complexing berberine hydrochloride with synergistic molecules, particularly silymarin, to enhance its therapeutic efficacy. The formulation incorporated coconut milk containing proteins and lipids through an advanced bionanotechnology approach. Morphological analysis via scanning electron microscope (SEM) and transmission electron microscopy (TEM) confirmed that BerbiQ consists of spherical, well-dispersed particles with smooth surfaces and no aggregation, indicative of successful berberine complexation. Additional characterization using Fourier transform infrared spectroscopy (FTIR), X-ray diffraction (XRD), and differential scanning calorimetry (DSC) analyses, along with stability studies, validated the effective complexation and stability of berberine hydrochloride within the BerbiQ formulation. Pharmacokinetic studies revealed that BerbiQ significantly enhances the oral bioavailability of berberine compared to conventional formulations, demonstrating a 4.26-fold increase in area under the curve (AUC) and a 4.10-fold increase in maximum plasma concentration (
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.